Main content

    Lung Cancer Clinical Trials

    CPMC Cancer Services Opens new window

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at

    Active Trials

    Title: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
    Decscription: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with a pathologically proven squamous cell non-small cell lung cancer (NSCLC) confirmed by tumor biopsy and/or fine-needle aspiration; disease must be either advanced, incurable stage IIIB or stage IV NSCLC
    Status: Contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: about Study SWOG 1400

    Title: A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
    Decscription: The purpose of this study is to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, with histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery, or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy)
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: about Study Incyte 266

    • updated October 2014

    Back to top